Scientific Research An Academic Publisher
OPEN ACCESS
Add your e-mail address to receive free newsletters from SCIRP.
Select Journal AA AAD AAR AASoci AAST ABB ABC ABCR ACES ACS ACT AD ADR AE AER AHS AID AiM AIT AJAC AJC AJCC AJCM AJIBM AJMB AJOR AJPS ALAMT ALC ALS AM AMI AMPC ANP APD APE APM ARS ARSci AS ASM BLR CC CE CellBio ChnStd CM CMB CN CRCM CS CSTA CUS CWEEE Detection EMAE ENG EPE ETSN FMAR FNS GEP GIS GM Graphene GSC Health IB ICA IIM IJAA IJAMSC IJCCE IJCM IJCNS IJG IJIDS IJIS IJMNTA IJMPCERO IJNM IJOC IJOHNS InfraMatics JACEN JAMP JASMI JBBS JBCPR JBiSE JBM JBNB JBPC JCC JCDSA JCPT JCT JDAIP JDM JEAS JECTC JEMAA JEP JFCMV JFRM JGIS JHEPGC JHRSS JIBTVA JILSA JIS JMF JMGBND JMMCE JMP JPEE JQIS JSBS JSEA JSEMAT JSIP JSS JSSM JST JTR JTST JTTs JWARP LCE MC ME MI MME MNSMS MPS MR MRC MRI MSA MSCE NJGC NM NR NS OALib OALibJ ODEM OJA OJAB OJAcct OJAnes OJAP OJApo OJAppS OJAPr OJAS OJBD OJBIPHY OJBM OJC OJCB OJCD OJCE OJCM OJD OJDer OJDM OJE OJEE OJEM OJEMD OJEpi OJER OJF OJFD OJG OJGas OJGen OJI OJIC OJIM OJINM OJL OJM OJMC OJMetal OJMH OJMI OJMIP OJML OJMM OJMN OJMP OJMS OJMSi OJN OJNeph OJO OJOG OJOGas OJOp OJOph OJOPM OJOTS OJPathology OJPC OJPChem OJPed OJPM OJPP OJPS OJPsych OJRA OJRad OJRD OJRM OJS OJSS OJSST OJST OJSTA OJTR OJTS OJU OJVM OPJ POS PP PST PSYCH SAR SCD SGRE SM SN SNL Soft SS TEL TI UOAJ VP WET WJA WJCD WJCMP WJCS WJET WJM WJNS WJNSE WJNST WJV WSN YM
More>>
Hardman, T.C. and Dubrey, S.W. (2011) Development and Potential Role of Type-2 Sodium-Glucose Transporter Inhibitors for Management of Type 2 Diabetes. Diabetes Therapy, 2, 133-145. http://dx.doi.org/10.1007/s13300-011-0004-1
has been cited by the following article:
TITLE: Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors in Type 2 Diabetes: A Literature Review of Approved Products
AUTHORS: Lucio R. Volino, Eva Y. Pan, Rupal Patel Mansukhani
KEYWORDS: Canagliflozin, Dapagliflozin, SGLT2 Inhibitors, Type 2 Diabetes Mellitus, Empagliflozin
JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.11, October 27, 2014
ABSTRACT: Diabetes mellitus continues to be a major health issue worldwide. Despite all of the treatment options available on the market, many patients with diabetes fail to reach their treatment goals. Novel agents such as the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors show promise in effectively lowering blood glucose. Objective: To review the scientific literature for efficacy information regarding the use of approved SGLT2 inhibitors (canagliflozin, dapagliflozin and empagliflozin) in the treatment of Type 2 Diabetes Mellitus (T2DM). Methods: A MEDLINE (1950-August 2014) literature review was performed. All of the literature published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trial were also included. Meta-analysis type studies were not selected for this review. Conclusions: With an increasing prevalence and incidence of type 2 diabetes mellitus worldwide, there is an apparent need for effective therapeutic strategies to combat this chronic and progressive disease. SGLT2 inhibitors offer this potential. Recently approved agents (canagliflozin, dapagliflozin and empagliflozin) have shown significant promise as mono- and add-on therapy to current glucose-lowering regimens that may not otherwise be providing sufficient glycemic control in T2DM patients.
Related Articles:
The Role of Inhaled Insulin in the Management of Type 2 Diabetes
Wesley Nuffer, Jennifer Trujillo
DOI: 10.4236/pp.2016.74021 2,657 Downloads 4,021 Views Citations
Pub. Date: April 21, 2016
On the Role of Spirituality and Religiosity in Type 2 Diabetes Mellitus Management—A Systematic Review
Panagiota Darvyri, Stavros Christodoulakis, Michael Galanakis, Adamantios G. Avgoustidis, Anastasia Thanopoulou, George P. Chrousos
DOI: 10.4236/psych.2018.94046 1,419 Downloads 2,982 Views Citations
Pub. Date: April 23, 2018
Obesity and type 2 diabetes
Subhashini Yaturu
DOI: 10.4236/jdm.2011.14012 12,869 Downloads 29,772 Views Citations
Pub. Date: November 8, 2011
The Role of Physical Counselling in Patients with Type 2 Diabetes Mellitus: A Systematic Review
Elisabetta Carraro, Mattia Roppolo, Sara Bonetta, Giorgio Gilli
DOI: 10.4236/jdm.2015.52012 3,871 Downloads 5,042 Views Citations
Pub. Date: May 8, 2015
The Level and Role of Interleukin-17 in Patients of Type 2 Diabetes Mellitus with and without Complications
Ashirbad Parhi, Sidhartha Das, Srikrushna Mahapatra, Nikhilesh Pradhan, Manoranjan Behera, Bijan Patnaik, Roma Rattan
DOI: 10.4236/jdm.2019.94017 355 Downloads 663 Views Citations
Pub. Date: November 28, 2019
